e-learning
resources
Milan 2017
Wednesday, 13.09.2017
Controversies in community-acquired pneumonia: a pro and con debate
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Should steroids be used in community-acquired pneumonia? Con argument
Grant Waterer (Perth, WA, Australia)
Source:
International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Session:
Controversies in community-acquired pneumonia: a pro and con debate
Session type:
Symposium
Number:
4800
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Grant Waterer (Perth, WA, Australia). Should steroids be used in community-acquired pneumonia? Con argument. International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Should macrolides be given to all patients with community-acquired pneumonia? Con argument
Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Year: 2017
Should steroids be used in community-acquired pneumonia? Pro argument
Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Year: 2017
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Corticosteroids for community-acquired pneumonia: are we still there?
Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment
Year: 2019
What is pneumonia?
Source: Breathe, 17 (3) 210087; 10.1183/20734735.0087-2021
Year: 2021
Should macrolides be given to all patients with community-acquired pneumonia? Pro argument
Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Year: 2017
Corticosteroids and community-acquired pneumonia
Source: Annual Congress 2007 - Corticosteroids and respiratory failure
Year: 2007
Critical illness-related corticosteroid insufficiency and community-acquired pneumonia: back to the future!
Source: Eur Respir J 2008; 31: 1150-1152
Year: 2008
Low-dose corticosteroids during severe community-acquired pneumonia: end of the story
Source: Eur Respir J 2015; 45: 305-307
Year: 2015
The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008
Intravenous steroids in the treatment of community-acquired pneumonia (CAP)
Source: Eur Respir J 2004; 24: Suppl. 48, 50s
Year: 2004
Corticosteroids in severe pneumonia
Source: Eur Respir J 2008; 32: 259-264
Year: 2008
Corticosteroids for community-acquired pneumonia: a critical view of the evidence
Source: Eur Respir J 2016; 48: 984-986
Year: 2016
Efficacy of corticosteroids in hospital treated community-acquired pneumonia
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Mixed community-acquired pneumonia in hospitalised patients
Source: Eur Respir J 2006; 27: 795-800
Year: 2006
Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?
Source: Eur Respir Rev, 29 (157) 200023; 10.1183/16000617.0023-2020
Year: 2020
Systemic corticosteroid for treating severe community-acquired pneumonia
Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept